Search clinical trials for: Gemtuzumab Ozogamicin

Total 802 results

Hoffmann-La Roche

Completed

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Ovarian Cancer

Italy, Austria, Belgium, France, Germany, Spain, Netherlands, Sweden, Denmark, Norway
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Terminated

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE (REGALE)

Leukemia | Myeloproliferative Disorders | Hodgkin Lymphoma | Non Hodgkin Lymphoma

United States
GlaxoSmithKline

Completed

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

Migraine | Migraine Disorders

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Chronic Granulomatous Disease

United States
Hanyang University Seoul Hospital

Unknown

Vortioxetine for Treatment of Depressive Mood and Alcohol Use

Alcoholism | Depressive Disorder, Major

Korea, Republic of
Damiano Rondelli, MD

Terminated

SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD (SCD-Haplo)

Sickle Cell Disease

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Myelodysplastic Syndromes | Leukemia | Congenital Amegakaryocytic Thrombocytopenia | Severe Congenital Neutropenia | Diamond-blackfan Anemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States, Italy
Paul Szabolcs

Recruiting

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Sickle Cell Anemia | Diamond-blackfan Anemia | Beta-thalassemia Major

United States
Paul Szabolcs

Recruiting

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Idiopathic Pulmonary Fibrosis | Emphysema or COPD

United States
Dana-Farber Cancer Institute
GlaxoSmithKline; National Comprehensive Cancer Network

Terminated

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

CLL | SLL

United States
ETOP IBCSG Partners Foundation
Pfizer; Hoffmann-La Roche

Completed

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH)

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

France, Switzerland, Belgium, Italy
Allan D Kirk, MD, PhD
Bristol-Myers Squibb; Duke University

Completed

Belatacept Post Depletional Repopulation to Facilitate Tolerance

Organ Transplantation

United States
Johns Hopkins University
Patient-Centered Outcomes Research Institute; National Multiple Sclerosis Society

Recruiting

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)

Multiple Sclerosis, Relapsing-Remitting

United States
Shengjing Hospital

Recruiting

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (PANSY)

Breast Cancer

China
Genentech, Inc.
Hoffmann-La Roche

Recruiting

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Neoplasm Metastasis

Australia, Korea, Republic of, China, United States, Portugal, Brazil, Singapore, Spain, United Kingdom, Belgium, Austria, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Me... and more
Otto Metzger, MD
Genentech, Inc.

Active, not recruiting

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Randy Windreich

Completed

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant (HSCT)

United States
The Methodist Hospital Research Institute
Novartis; Celgene Corporation

Completed

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel (TEAL)

Breast Cancer

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Sickle Cell Anemia | Beta Thalassemia

United States
Second Affiliated Hospital, School of Medicine,...
Sun Yat-sen University; Peking University International Hospital; Zhejiang University

Not yet recruiting

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

HER2-positive Breast Cancer | Brain Metastases

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Breast Cancer

China
NSABP Foundation Inc
Genentech, Inc.; Celcuity, LLC

Recruiting

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

HER2-negative Breast Cancer

United States
Dana-Farber Cancer Institute

Active, not recruiting

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Breast Cancer

United States
Karolinska Institutet
Patient-Centered Outcomes Research Institute; Kaiser Foundation Research Institute

Active, not recruiting

COMparison Between All immunoTherapies for Multiple Sclerosis. (COMBAT-MS)

Relapsing-remitting Multiple Sclerosis

Sweden
Masonic Cancer Center, University of Minnesota

Completed

Allogeneic Transplantation For Severe Osteopetrosis

Severe Osteopetrosis

United States
University of Miami
Immune Tolerance Network (ITN)

Completed

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

Kidney Transplantation | Kidney Failure | Kidney Disease

United States
Genzyme, a Sanofi Company

Completed

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (EMERALD)

Relapsing-remitting Multiple Sclerosis

Belgium, Spain, France, Netherlands
American Society of Clinical Oncology
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; Merck Sharp & Dohme LLC; Pfizer; AstraZene... and other collaborators

Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Advanced Solid Tumors

United States
Fudan University

Recruiting

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

HER2 Positive Early Breast Cancer

China
MedSIR

Active, not recruiting

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain)

Breast Cancer

Spain, Italy, France, United Kingdom, Germany, Portugal, Belgium
Japan Breast Cancer Research Group
Chugai Pharmaceutical

Unknown

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer

Japan
Grupo Español de Linfomas y Transplante Autólogo...

Terminated

Cyclosporine Plus Methotrexate or Alemtuzumab

Unrecognized Condition: Mature B or T-cell Neoplasm

Spain, Poland
GlaxoSmithKline

Completed

Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents

Migraine Disorders

United States
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Completed

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients (TILT)

Liver Transplantation | Liver Disease

United States, Canada
University Health Network, Toronto
Bayer

Completed

Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants

Bone Marrow Transplantation | Graft Versus Host Disease

Canada
Novartis

Completed

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

Hypertension

Germany, Switzerland
wang shusen

Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002)

Breast Neoplasms

China
Genentech, Inc.

Active, not recruiting

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Breast Cancer | Solid Tumor

United States, France, Spain, United Kingdom, Canada
Icahn School of Medicine at Mount Sinai

Terminated

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Locally Advanced Breast Cancer

United States
Midwestern Regional Medical Center

Unknown

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT)

Breast Neoplasms

United States
Massachusetts General Hospital

Completed

Effects of Pennsaid on Clinical Neuropathic Pain

Neuralgia | Reflex Sympathetic Dystrophy | Postherpetic Neuralgia | Complex Regional Pain Syndrome (CRPS)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States, Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

Primary Immune Deficiency Disorder | Bone Marrow Failure | Immune Deficiency Disease

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Sickle Cell Anemia | Thalassemia | Hemoglobinopathy

United States
The Cleveland Clinic
University of Nottingham

Active, not recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors

Brain and Central Nervous System Tumors | Neuroblastoma

United States
Technische Universität Dresden
Pfizer; Novartis Pharmaceuticals

Recruiting

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC)

Acute Myeloid Leukemia

Germany
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Lung Cancer

United States

Search clinical trials for: Gemtuzumab Ozogamicin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations